Insider · CIK 0001307729

Baker Brothers Life Sciences Capital (Gp), LLC

CIK 0001307729 Name as filed on the most recent filing

Filed as Baker Brothers Life Sciences Capital (Gp), LLC (174)· Baker Biotech Capital III (Gp), LLC (12)

647 transaction lines · from 186 filings · filed 2005-02-14 to 2012-03-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2008-06-09 P, Open-market purchase Genomic Health IncGHDX 4 lines 1,280,112, acquired Open Form 4 filing 0001144204-08-034282
2008-06-06 P, Open-market purchase Genomic Health IncGHDX 2 lines 3,212,600, acquired Open Form 4 filing 0001144204-08-034282
2008-06-05 P, Open-market purchase Genomic Health IncGHDX 2 lines 1,899,293, acquired Open Form 4 filing 0001144204-08-034282
2008-05-22 P, Open-market purchase Allos Therapeutics IncALTH 6,466,046, acquired Open Form 4 filing 0001144204-08-032228
2008-04-17 P, Open-market purchase Ardea Biosciences, Inc./DERDEA 371,601, acquired Open Form 4 filing 0001144204-08-023490
2008-04-04 P, Open-market purchase Ardea Biosciences, Inc./DERDEA 4,158,884, acquired Open Form 4 filing 0001144204-08-021207
2008-04-03 S, Open-market sale Tapestry Pharmaceuticals, IncTPPH 2,557, disposed Open Form 4 filing 0001144204-08-021220
2008-03-18 P, Open-market purchase Seattle Genetics Inc /WASGEN 423,038, acquired Open Form 4 filing 0001144204-08-016450
2008-03-17 P, Open-market purchase Seattle Genetics Inc /WASGEN 551,968, acquired Open Form 4 filing 0001144204-08-016450
2008-03-17 P, Open-market purchase Viropharma IncVPHM 46,464, acquired Open Form 4 filing 0001144204-08-015926
2008-03-14 P, Open-market purchase Seattle Genetics Inc /WASGEN 2 lines 997,429, acquired Open Form 4 filing 0001144204-08-015451
2008-03-14 P, Open-market purchase Viropharma IncVPHM 30,642, acquired Open Form 4 filing 0001144204-08-015926
2008-03-13 P, Open-market purchase Seattle Genetics Inc /WASGEN 304,356, acquired Open Form 4 filing 0001144204-08-015451
2008-03-13 P, Open-market purchase Viropharma IncVPHM 435,755, acquired Open Form 4 filing 0001144204-08-015926
2008-03-12 P, Open-market purchase Seattle Genetics Inc /WASGEN 91,589, acquired Open Form 4 filing 0001144204-08-015451
2008-02-25 P, Open-market purchase Allos Therapeutics IncALTH 510,330, acquired Open Form 4 filing 0001144204-08-012091
2008-02-21 P, Open-market purchase Allos Therapeutics IncALTH 2 lines 745,509, acquired Open Form 4 filing 0001144204-08-011225
2008-02-20 P, Open-market purchase Allos Therapeutics IncALTH 421,324, acquired Open Form 4 filing 0001144204-08-011225
2008-02-19 P, Open-market purchase Allos Therapeutics IncALTH 433,973, acquired Open Form 4 filing 0001144204-08-011225
2008-02-11 P, Open-market purchase Seattle Genetics Inc /WASGEN 345,119, acquired Open Form 4 filing 0001144204-08-007637
2008-02-08 P, Open-market purchase Seattle Genetics Inc /WASGEN 2 lines 807,257, acquired Open Form 4 filing 0001144204-08-007637
2008-02-07 P, Open-market purchase Seattle Genetics Inc /WASGEN 231,681, acquired Open Form 4 filing 0001144204-08-007637
2008-01-23 P, Open-market purchase Allos Therapeutics IncALTH 136,305, acquired Open Form 4 filing 0001144204-08-003627
2008-01-23 P, Open-market purchase Seattle Genetics Inc /WASGEN 864,105, acquired Open Form 4 filing 0001144204-08-003619
2008-01-22 P, Open-market purchase Incyte CorpINCY 2,368, acquired Open Form 4 filing 0001144204-08-003837
2008-01-22 P, Open-market purchase Allos Therapeutics IncALTH 3,838, acquired Open Form 4 filing 0001144204-08-003627
2008-01-22 P, Open-market purchase Seattle Genetics Inc /WASGEN 571,758, acquired Open Form 4 filing 0001144204-08-003619
2008-01-18 P, Open-market purchase Allos Therapeutics IncALTH 2 lines 66,389, acquired Open Form 4 filing 0001144204-08-003627
2008-01-18 P, Open-market purchase Seattle Genetics Inc /WASGEN 17,400,807, acquired Open Form 4 filing 0001144204-08-003619
2008-01-15 P, Open-market purchase Allos Therapeutics IncALTH 145,005, acquired Open Form 4 filing 0001144204-08-002830
2008-01-14 P, Open-market purchase Allos Therapeutics IncALTH 664,603, acquired Open Form 4 filing 0001144204-08-002240
2008-01-14 P, Open-market purchase Incyte CorpINCY 380,398, acquired Open Form 4 filing 0001144204-08-002620
2008-01-11 P, Open-market purchase Allos Therapeutics IncALTH 283,387, acquired Open Form 4 filing 0001144204-08-002240
2008-01-11 P, Open-market purchase Incyte CorpINCY 335,548, acquired Open Form 4 filing 0001144204-08-001871
2008-01-10 P, Open-market purchase Allos Therapeutics IncALTH 596,348, acquired Open Form 4 filing 0001144204-08-002240
2008-01-10 S, Open-market sale Idera Pharmaceuticals, Inc.IDP 5,591, disposed Open Form 4 filing 0001144204-08-002156
2008-01-10 P, Open-market purchase Incyte CorpINCY 13,657, acquired Open Form 4 filing 0001144204-08-001871
2008-01-09 S, Open-market sale Idera Pharmaceuticals, Inc.IDP 28,771, disposed Open Form 4 filing 0001144204-08-001415
2008-01-09 P, Open-market purchase Incyte CorpINCY 991,319, acquired Open Form 4 filing 0001144204-08-001871
2008-01-09 P, Open-market purchase Allos Therapeutics IncALTH 299,449, acquired Open Form 4 filing 0001144204-08-001430
2008-01-09 P, Open-market purchase Viropharma IncVPHM 630,399, acquired Open Form 4 filing 0001144204-08-001591

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Baker Brothers Life Sciences Capital (GP), LLC, insider transactions. Retrieved 2026-08-28 from https://ebomi.com/insider/0001307729

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.